OKYO Pharma Limited
NASDAQ:OKYO
Overview | Financials
Company Name | OKYO Pharma Limited |
Symbol | OKYO |
Currency | USD |
Price | 1.065 |
Market Cap | 36,088,924 |
Dividend Yield | 0% |
52-week-range | 0.808 - 1.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gary S. Jacob Ph.D. |
Website | https://www.okyopharma.com |
An error occurred while fetching data.
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD